FluMist

Vaccine: FluMist
Company: MedImmune
Approval Date: June 20
Protects Against: Influenza

MedImmune, maker of the nasal spray influenza vaccine FluMist, entered the 2012-2013 flu season well-prepared; the company says it has 620,000 extra doses on hand during a time when flu vaccines are in demand and running low. Approved for individuals ages 2 to 49, the vaccine first entered the market in 2003. The spray vaccine differs from its needle-delivered counterparts in that it allows patients to avoid a painful or uncomfortable shot. In 2012, FluMist sales hit an estimated $162 million.

In May 2012, MedImmune teamed with Hemispherx Biopharma ($HEB) to test that company's RNA-based adjuvant, Ampligen, intranasally in combination with FluMist. Preclinical research conducted in Japan showed that Ampligen could amplify immune response to influenza vaccines.

For more:
Special Report: Top 10 selling flu vaccines of 2012
Ampligen-FluMist nasal trial begins
Vaccine maker MedImmune has a new AZ chief
AstraZeneca's FluMist Quadrivalent to hit U.S. market

FluMist
Read more on

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.